Cargando…
Mice with an Oncogenic HRAS Mutation are Resistant to High-Fat Diet-Induced Obesity and Exhibit Impaired Hepatic Energy Homeostasis
Costello syndrome is a “RASopathy” that is characterized by growth retardation, dysmorphic facial appearance, hypertrophic cardiomyopathy and tumor predisposition. > 80% of patients with Costello syndrome harbor a heterozygous germline G12S mutation in HRAS. Altered metabolic regulation has been...
Autores principales: | Oba, Daiju, Inoue, Shin-ichi, Miyagawa-Tomita, Sachiko, Nakashima, Yasumi, Niihori, Tetsuya, Yamaguchi, Seiji, Matsubara, Yoichi, Aoki, Yoko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828294/ https://www.ncbi.nlm.nih.gov/pubmed/29254681 http://dx.doi.org/10.1016/j.ebiom.2017.11.029 |
Ejemplares similares
-
New Noonan syndrome model mice with RIT1 mutation exhibit cardiac hypertrophy and susceptibility to β-adrenergic stimulation-induced cardiac fibrosis
por: Takahara, Shingo, et al.
Publicado: (2019) -
Costello syndrome model mice with a Hras(G12S/+) mutation are susceptible to develop house dust mite-induced atopic dermatitis
por: Katata, Yu, et al.
Publicado: (2020) -
MTH1 expression is required for effective transformation by oncogenic HRAS
por: Giribaldi, Maria G., et al.
Publicado: (2015) -
Pterostilbene Sensitizes Cisplatin-Resistant Human Bladder Cancer Cells with Oncogenic HRAS
por: Chen, Yi-Ting, et al.
Publicado: (2020) -
TBX1 Mutation Identified by Exome Sequencing in a Japanese Family with 22q11.2 Deletion Syndrome-Like Craniofacial Features and Hypocalcemia
por: Ogata, Tsutomu, et al.
Publicado: (2014)